Santamarina Aline Boveto, Moraes Ruan Carlos Macêdo, Nehmi Filho Victor, Murata Gilson Masahiro, de Freitas Jéssica Alves, de Miranda Danielle Araujo, Cerqueira Anderson Romério Azevedo, Costa Soraia Katia Pereira, Ferreira Ana Flávia Fernandes, Britto Luiz Roberto, de Camargo Juliana Alves, Rodrigues de Oliveira Daniela, de Jesus Flavia Neto, Otoch José Pinhata, Pessoa Ana Flávia Marçal
Department of Biosciences, Federal University of São Paulo (UNIFESP), Santos 11015-020, SP, Brazil.
Natural Products and Derivatives Laboratory (LIM-26), Department of Surgery, University of São Paulo Medical School, São Paulo 01246-903, SP, Brazil.
Antioxidants (Basel). 2022 Feb 23;11(3):447. doi: 10.3390/antiox11030447.
The use of natural products and derivatives for the prevention and control of non-communicable chronic diseases, such as type-2 diabetes (T2D), obesity, and hepatic steatosis is a way to achieve homeostasis through different metabolic pathways. Thus, male C57BL/6 mice were divided into the following groups: high-fat diet (HFD) vehicle, HFD + Supplemented, HFD + Supplemented_S, and isolated compounds. The vehicle and experimental formulations were administered orally by gavage once a day over the four weeks of the diet (28 consecutive days). We evaluated the energy homeostasis, cytokines, and mitochondrial gene expression in these groups of mice. After four weeks of supplementation, only the new nutraceutical group (HFD + Supplemented) experienced reduced fasting glycemia, insulin, HOMA index, HOMA-β, dyslipidemia, ectopic fat deposition, and hepatic fibrosis levels. Additionally, the PPARγ coactivator 1 α (), interleukin-6 and interleukin-10 ) gene expression were augmented, while hepatic steatosis decreased and liver parenchyma was recovered. The glutathione-S-transferase activity status was found to be modulated by the supplement. We discovered that the new nutraceutical was able to improve insulin resistance and hepatic steatosis mainly by regulating , and gene expression.
使用天然产物及其衍生物预防和控制非传染性慢性病，如2型糖尿病（T2D）、肥胖症和肝脂肪变性，是通过不同代谢途径实现体内平衡的一种方式。因此，将雄性C57BL/6小鼠分为以下几组：高脂饮食（HFD）载体组、HFD + 补充剂组、HFD + 补充剂_S组和分离化合物组。在四周的饮食期间（连续28天），每天通过灌胃法口服给予载体和实验制剂。我们评估了这些小鼠组中的能量平衡、细胞因子和线粒体基因表达情况。补充四周后，只有新营养制剂组（HFD + 补充剂组）的空腹血糖、胰岛素水平、HOMA指数、HOMA-β、血脂异常、异位脂肪沉积和肝纤维化水平有所降低。此外，PPARγ共激活因子1α（）、白细胞介素-6 （）和白细胞介素-10（）的基因表达增加，同时肝脂肪变性减轻，肝实质得以恢复。发现谷胱甘肽-S-转移酶活性状态受该补充剂调节。我们发现，新营养制剂主要通过调节、和基因表达来改善胰岛素抵抗和肝脂肪变性。
